Experimental therapies under investigation for COVID-19

References

• Andersen KG, Rambaut A, Lipkin WI, et al. The proximal origin of sars-cov-2 Nat Med. 2020Apr.264:450–452 Available fromhttps://www.nature.com/articles/s41591-020-0820–910.1038/s41591-020-0820-9
   Web of Science ®Google Scholar
• Cheng VCC, Chan JFW, To KKW, et al. Clinical management and infection control of sars: lessons learned. Antiviral Res. Nov 1 2013;100:407–419. Available from http://www.sciencedirect.com/science/article/pii/S016635421300224610.1016/j.antiviral.2013.08.016 2
   PubMed Web of Science ®Google Scholar
• Mustafa S, Balkhy H, Gabere MN. Current treatment options and the role of peptides as potential therapeutic components for middle east respiratory syndrome (mers): a review. J Infect Public Health. 2018;11(1):9–17. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102797/10.1016/j.jiph.2017.08.009
   PubMed Web of Science ®Google Scholar
• Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273. Available from. .
   PubMed Web of Science ®Google Scholar
• Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-ncov outbreak originating in wuhan, china: a modelling study. Lancet Lond Engl. 202029;395(10225):689–697.
   PubMed Web of Science ®Google Scholar
• Lai -C-C, Shih T-P, Ko W-C, et al. Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) and coronavirus disease-2019 (covid-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020 Mar; 55(3):105924.
   Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. Sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor. Cell. 2020Mar 4;10.1016/j.cell.2020.02.052
   Web of Science ®Google Scholar
• Diao B, Wang C, Tan Y, et al. Reduction and functional exhaustion of t cells in patients with coronavirus disease 2019 (covid-19). medrxiv. 2020Feb 20;2020.02.18.20024364. Available from: https://www.medrxiv.org/content/10.1101/2020.02.18.20024364v1
   Google Scholar
• To KK-W, Tsang OT-Y, Leung W-S et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by sars-cov-2: an observational cohort study. Lancet Infect Dis. 2020Mar23 Available fromhttps://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30196-1/abstract
   Web of Science ®Google Scholar
• Cunningham AC, Goh HP, Koh D. Treatment of COVID-19: old tricks for new challenges. Crit Care Lond Engl. 202016;24(1):91.
   PubMed Web of Science ®Google Scholar
• Liu Y, Li J, Feng Y. Critical care response to a hospital outbreak of the 2019-ncov infection in shenzhen, china Crit Care. 2020 Feb19.241:56 Available from10.1186/s13054-020-2786-x10.1186/s13054-020-2786-x
   Web of Science ®Google Scholar
• Vincent MJ, Bergeron E, Benjannet S et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005Aug22 21 69 Available from10.1186/1743-422X-2-6910.1186/1743-422X-2-69
   Google Scholar
• Wang M, Cao R, Zhang L et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar 30(3) 269–271 Available fromhttps://www.nature.com/articles/s41422-020-0282–010.1038/s41422-020-0282-0
   Web of Science ®Google Scholar
• Cortegiani A, Ingoglia G, Ippolito M, et al. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020Mar10 Available from http://www.sciencedirect.com/science/article/pii/S0883944120303907
   Google Scholar
• Gautret P, Lagier J-C, Parola P et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Mar20 Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102549/1 10.1016/j.ijantimicag.2020.105949
   Web of Science ®Google Scholar
• Chen J, Liu D, Liu L et al. [A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19]. Zhejiang Xue Xue Bao Yi Xue Ban J Zhejiang Univ Med Sci 2020 May 25;492:215–219
   Google Scholar
• Molina JM, Delaugerre C, Le goff J et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Médecine Mal Infect. 2020Mar30 Available fromhttp://www.sciencedirect.com/science/article/pii/S0399077X2030085810.1016/j.medmal.2020.03.0064
   Web of Science ®Google Scholar
• Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with covid-19. N Engl J Med [ null. Available from]. 2020 May7. : 10.1056/NEJMoa2012410
   Web of Science ®Google Scholar
• Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for covid-19. N Engl J Med. 2020Aug6 383(6):517–525. Available from
   Web of Science ®Google Scholar
• Agostini ML, Andres EL, Sims AC et al. Coronavirus susceptibility to the antiviral remdesivir (gs-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 2018Mar6 92 Available fromhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844999/10.1128/mBio.00221-18
   Web of Science ®Google Scholar
• Brown AJ, Won JJ, Graham RL, et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral Res. 2019;169:104541.
   PubMed Web of Science ®Google Scholar
• Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 201728;9(396):396. .
   Web of Science ®Google Scholar
• Wit E D, Feldmann F, Cronin J et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci. 2020Mar24 11712 6771–6776 Available fromhttps://www.pnas.org/content/117/12/677110.1073/pnas.1922083117
   Web of Science ®Google Scholar
• Holshue ML, DeBolt C, Lindquist S et al. First case of 2019 novel coronavirus in the usa. N Engl J Med. 2020Jan 31 Available fromhttps://www.nejm.org/doi/10.1056/NEJMoa200119110.1056/NEJMoa200119110
   Web of Science ®Google Scholar
• Wang Y, Zhang D, Du G et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020Apr29 Available fromhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31022-9/abstract
   Web of Science ®Google Scholar
• Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe covid-19. N Engl J Med. 2020Nov5 383(19):1827–1837. Available from
   Web of Science ®Google Scholar
• Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe covid-19. N Engl J Med. 2020 Jun11 382(24):2327–2336. Available from
   Web of Science ®Google Scholar
• Beigel JH, Tomashek KM, Dodd LE et al. Remdesivir for the treatment of covid-19 — preliminary report. N Engl J Med. 2020 May22 null. Available from 10.1056/NEJMoa2007764
   Google Scholar
• Repurposed antiviral drugs for covid-19 — interim who solidarity trial results. N Engl J Med. 2020Dec2 null. Available from 10.1056/NEJMoa2023184
   Web of Science ®Google Scholar
• Furuta Y, Takahashi K, Fukuda Y, et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother. 2002 Apr 46;(4)977–981.
   Web of Science ®Google Scholar
• Cai Q, Yang M, Liu D et al. Experimental treatment with favipiravir for covid-19: an open-label control study. Eng Beijing China. 2020Mar18; Available from. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185795/
   Google Scholar
• Chen C, Huang J, Yin P et al. Favipiravir versus arbidol for covid-19: a randomized clinical trial. medRxiv. 2020Apr8 2020.03.17.20037432Available fromhttps://www.medrxiv.org/content/10.1101/2020.03.17.20037432v3
   Google Scholar
• Chinese clinical trial register (chictr) - the world health organization international clinical trials registered organization registered platform. Available from: http://www.chictr.org.cn/showprojen.aspx?proj=49042
   Google Scholar
• Chinese clinical trial register (chictr) - the world health organization international clinical trials registered organization registered platform. Available from: http://www.chictr.org.cn/showprojen.aspx?proj=49013
   Google Scholar
• Hensley LE, Fritz LE, Jahrling PB, et al. Interferon-beta 1a and SARS coronavirus replication. Emerg Infect Dis. 2004 Feb; 10(2):317–319.
   Web of Science ®Google Scholar
• Chan JFW, Chan K-H, Kao RYT, et al. Broad-spectrum antivirals for the emerging middle east respiratory syndrome coronavirus. J Infect. 2013 Dec 67;(6)606–616.
   Web of Science ®Google Scholar
• Lokugamage KG, Hage A, Schindewolf C, et al. Sars-cov-2 is sensitive to type i interferon pretreatment. bioRxiv. 2020Mar18 2020.03.07.982264Available fromhttps://www.biorxiv.org/content/10.1101/2020.03.07.982264v2
   Google Scholar
• National Institute of Allergy and Infectious Diseases (NIAID). A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-3). ; 2020 Sep. Report No.: NCT04492475. Available from: https://clinicaltrials.gov/ct2/show/NCT04492475 clinicaltrials.gov
   Google Scholar
• Davoudi-monfared E, Rahmani H, Khalili H et al. Efficacy and safety of interferon beta-1a in treatment of severe COVID-19: A randomized clinical trial. medRxiv. 2020May30 2020.05.28.20116467Available fromhttps://www.medrxiv.org/content/10.1101/2020.05.28.20116467v1
   Google Scholar
• Cao B, Wang Y, Wen D et al. A trial of lopinavir–ritonavir in adults hospitalized with severe covid-19. N Engl J Med. 2020Mar18 null. Available from 10.1056/NEJMoa2001282
   Web of Science ®Google Scholar
• Baden LR, Rubin EJ. Covid-19 — the search for effective therapy. N Engl J Med. 2020Mar18 Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121446/19 10.1056/NEJMe2005477
   Web of Science ®Google Scholar
• Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression Lancet. 2020Mar28.39510229:1033–1034 Available fromhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30628-0/abstract10.1016/S0140-6736(20)30628-0
   Web of Science ®Google Scholar
• Guaraldi G, Meschiari M, Cozzi-lepri A et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020Jun24 Available fromhttps://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30173-9/abstract
   Google Scholar
• Biran N, Ip A, Ahn J et al. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. Lancet Rheumatol. 2020Oct1 210 e603–12 Available fromhttps://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30277-0/abstract10.1016/S2665-9913(20)30277-0
   Google Scholar
• Stone JH, Frigault MJ, Serling-boyd NJ, et al. Efficacy of tocilizumab in patients hospitalized with covid-19. N Engl J Med. 2020Dec10 383(24):2333–2344. Available from
   PubMed Web of Science ®Google Scholar
• Lu L, Zhang H, Dauphars DJ, et al. A potential role of interleukin 10 in covid-19 pathogenesis. Trends Immunol. [2020Oct31]. Available from: https://www.cell.com/trends/immunology/abstract/S1471-4906(20)30256–8
   Web of Science ®Google Scholar
• Chan JF-W, Yao Y, Yeung M-L, et al. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of mers-cov infection in a nonhuman primate model of common marmoset. J Infect Dis. 2015 Dec15 212;(12)1904–1913.
   Web of Science ®Google Scholar
• Shen C, Wang Z, Zhao F et al. Treatment of 5 critically ill patients with covid-19 with convalescent plasma. JAMA. 2020Mar27 Available fromhttps://jamanetwork.com/journals/jama/fullarticle/276398310.1001/jama.2020.478316
   Web of Science ®Google Scholar
• Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening covid-19: a randomized clinical trial. JAMA. Available from: https://jamanetwork.com/journals/jama/fullarticle/2766943 2020 Jun3.
   Web of Science ®Google Scholar
• Wu C, Chen X, Cai Y et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in wuhan, china. JAMA Intern Med. 2020 Mar 13 Available fromhttps://jamanetwork.com/journals/jamainternalmedicine/fullarticle/276318410.1001/jamainternmed.2020.09947
   Web of Science ®Google Scholar
• Russell B, Moss C, Rigg A, et al. covid-19 and treatment with nsaids and corticosteroids: should we be limiting their use in the clinical setting? ecancermedicalscience. 14. [2020Mar 30]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105332/
   Web of Science ®Google Scholar
• Russell B, Moss C, George G et al. Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidence. ecancermedicalscience. 2020Mar 27 14 Available fromhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105343/10.3332/ecancer.2020.1022
   Web of Science ®Google Scholar
• Lu S, Zhou Q, Huang L et al. Effectiveness and safety of glucocorticoids to treat COVID-19: a rapid review and meta-analysis. Ann Transl Med. 2020 May 810 Available fromhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290628/10.21037/atm-20-3307
   Web of Science ®Google Scholar
• Horby P, Lim WS, Emberson J, et al. Effect of dexamethasone in hospitalized patients with covid-19: preliminary report. medRxiv. 2020Jun 22;2020.06.22.20137273. Available from: https://www.medrxiv.org/content/10.1101/2020.06.22.20137273v1
   Google Scholar
• Beigel JH, Nam HH, Adams PL et al. Advances in respiratory virus therapeutics – a meeting report from the 6th isirv antiviral group conference. Antiviral Res. 2019 Jul 167 45–67 Available fromhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132446/10.1016/j.antiviral.2019.04.006
   Web of Science ®Google Scholar
• Sars-cov-2 neutralizing antibody ly-cov555 in outpatients with covid-19 | NEJM. Available from:https://www.nejm.org/doi/full/10.1056/NEJMoa2029849
   Google Scholar
• Weinreich DM, Sivapalasingam S, Norton T, et al. Regn-cov2, a neutralizing antibody cocktail, in outpatients with covid-19. N Engl J Med. [2020Dec17]. Available from. 10.1056/NEJMoa2035002
   Web of Science ®Google Scholar
• Richardson PJ, Corbellino M, Stebbing J. Baricitinib for COVID-19: a suitable treatment? – authors’ reply. Lancet Infect Dis. [2020Apr3]. Available from: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30270-X/abstract
   Google Scholar
• Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with covid-19. N Engl J Med. 2020 Dec11: 10.1056/NEJMoa2031994 Available from.
   Web of Science ®Google Scholar
• Kawase M, Shirato K, van der hoek L, et al. Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry J Virol. 2012 Jun.8612:6537–6545 Available fromhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3393535/10.1128/JVI.00094-12
   Web of Science ®Google Scholar
• The impact of camostat mesilate on covid-19 infection - full text view - clinicaltrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT04321096
   Google Scholar
• Zhang Y, Ding J, Ren S, et al. Intravenous infusion of human umbilical cord wharton’s jelly-derived mesenchymal stem cells as a potential treatment for patients with covid-19 pneumonia. Stem Cell Res Ther. 202027;11(1):207. .
   Web of Science ®Google Scholar
• Treatment with mesenchymal stem cells for severe corona virus disease 2019(covid-19) - full text view - clinicaltrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT04288102
   Google Scholar
• Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020Apr1.84:e21 Available fromhttps://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30116-8/abstract10.1016/S2213-2600(20)30116-8
   Web of Science ®Google Scholar
• Elimination or prolongation of ace inhibitors and arb in coronavirus disease 2019 - full text view - clinicaltrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT04338009
   Google Scholar
• Research C for DE and. FDA advises patients on use of non-steroidal anti-inflammatory drugs (nsaids) for COVID-19. FDA. 2020Mar19; Available from:https://www.fda.gov/drugs/drug-safety-and-availability/fda-advises-patients-use-non-steroidal-anti-inflammatory-drugs-nsaids-covid–19
   Google Scholar
• Draft landscape of COVID-19 candidate vaccines. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
   Google Scholar